Brand work for companies that cannot overclaim.
We are a pharmaceutical branding agency working on corporate identity, rebrand rollout, scientific illustration and mechanism-of-action animation for regulated companies — where a brand has to feel confident without saying anything the label does not support.
Branding in this sector is constrained in an unusual way: the promise has to come from the evidence. That rules out most of the shortcuts other categories use.
In most sectors a brand can promise an outcome. In pharmaceutical branding it cannot: what may be said is bounded by the approved label, and corporate messaging is watched by the people who watch product claims.
Brand and corporate identity, naming, rebrand rollout, scientific illustration, mechanism-of-action animation, motion, congress material, investor decks and employer branding.
Deciding what may be claimed about a product, and producing promotional material requiring a regulatory sign-off role we do not hold. Scientific accuracy is validated by your team before anything ships.
We build the platforms an identity has to live on, which is where most rebrands actually come apart. For a pharmaceutical branding agency the real measure is how much estate the rollout had to cover.
A dermocosmetics line can behave like a consumer brand. A prescription laboratory cannot. In pharmaceutical branding the creative latitude is set by the category, not by ambition.
What comes up when a regulated company rebrands.
The promise has to be provable. Product claims are bounded by the approved label, and corporate messaging is reviewed by the same people who review those claims. The work moves towards evidence and clarity, and away from aspirational language that would not survive the first legal read.
With the rollout plan, not the logo. The hard questions are which entities keep their names, how the transition is communicated to professionals and partners, and in what order the digital estate changes. Getting the identity right and the sequencing wrong is what leaves a company looking inconsistent for a year.
Yes. It is one of the highest-value deliverables in the sector, and producing it well needs scientific rigour rather than regulatory licence on our side. We build the animation to the brief provided, and your scientific and regulatory teams validate every detail for accuracy before it is approved for external use.
Yes, and that is usually the reason companies come to us. Most rebrands lose momentum in application: sites, portals, country versions and templates that never fully change. We build those platforms, so the identity is applied rather than handed over as a PDF.
Almost always, and it is the standard situation for affiliates working under a global brand. The task shifts from defining identity to building the digital system the global guidelines never covered — components, interactive states, content hierarchies — so local teams can publish within the framework without waiting on head office for every decision.
We handle corporate and programme naming as part of the branding work. Naming an actual medicine is a separate, regulated process that involves trademark clearance and health-authority review in each market, so for that piece we work alongside specialist naming and regulatory consultants rather than running it ourselves.
A new identity, a rebrand after an acquisition, scientific illustration or mechanism-of-action animation. Tell us the context and we will tell you how we would approach the pharmaceutical branding work.